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Abstract PTEN, a tumor suppressor among the most com-
monly mutated proteins in human cancer, is recognized to be both
a protein phosphatase and a phosphatidylinositol 3,4,5-tris-
phosphate (PtdIns(3,4,5)P3) 3-phosphatase. Previous work
[Maehama and Dixon, J. Biol. Chem. 273 (1998) 13375^
13378] has led to a consensus that inositol phosphates are not
physiologically relevant substrates for PTEN. In contrast, we
demonstrate that PTEN is an active inositol 1,3,4,5,6-penta-
kisphosphate (Ins(1,3,4,5,6)P5) 3-phosphatase when expressed
and purified from bacteria or HEK cells. Kinetic data indicate
Ins(1,3,4,5,6)P5 (Km = 7.1 WM) and PtdIns(3,4,5)P3 (Km =
26 WM) compete for PTEN in vivo. Transient transfection of
HEK cells with PTEN decreased Ins(1,3,4,5,6)P5 levels. We
discuss the physiological significance of these studies in relation
to recent work showing that dephosphorylation of Ins-
(1,3,4,5,6)P5 to inositol 1,4,5,6-tetrakisphosphate is a cell
signaling event. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Signal transduction modules receive and transmit intracel-
lular information. Some proteins integrate multiple inputs
into a single output. Other proteins display ‘coincident signal-
ing’, by simultaneously regulating divergent signaling path-
ways. Together these processes provide signaling speci¢city
and regulate ‘cross-talk’ ; a challenge for signal transduction
research is to unravel the molecular processes involved.
Coincident signaling is undertaken by PTEN, a tumor sup-
pressor that ranks among the most commonly mutated pro-
teins in human cancer [1]. PTEN is both a protein phospha-
tase [2] and a phosphatidylinositol 3,4,5-trisphosphate
(PtdIns(3,4,5)P3) 3-phosphatase [3]. Dephosphorylation of fo-
cal adhesion kinase by PTEN inhibits cellular growth, inva-
sion, migration and focal adhesions [4]. PtdIns(3,4,5)P3 phos-
phatase activity of PTEN decreases cell proliferation and
antagonizes Akt-dependent cell survival [1]. However, in sev-
eral earlier studies, PTEN overexpression in cells was found to
have divergent e¡ects that could, for example, range from cell
cycle arrest to apoptosis, and it has been di⁄cult to reconcile
all of these e¡ects solely from PTEN’s inositol lipid and pro-
tein phosphatase activities [1]. Thus, evaluating if PTEN
might utilize further substrates has been promoted as an im-
portant challenge for future work with this protein [1].
A previous study concluded that PTEN showed negligible
activity towards the inositol 1,3,4,5-tetrakisphosphate (Ins-
(1,3,4,5)P4) head group of PtdIns(3,4,5)P3 (Km = 99 WM [3]).
Thus, there has not been any prior interest in the possibility
that PTEN might hydrolyze inositol phosphates. Indeed, it is
generally accepted that inositol phosphates and inositol lipids
are each predominantly metabolized by their own dedicated
kinases and phosphatases with no substantial cross-over in
substrate speci¢city. For example, the type I and II ‘3-phos-
phatases individually prefer either inositol 1,3-bisphosphate
(Ins(1,3)P2) or phosphatidylinositol 3-monophosphate respec-
tively [5]. The inositol lipid 4-phosphatases have only rela-
tively weak activities against Ins(1,3,4)P3 and Ins(3,4)P2 [6].
The type 1 5-phosphatase is specialized for hydrolyzing In-
s(1,4,5)P3 and Ins(1,3,4,5)P4, and has little activity against the
inositol lipids [7]. The other 5-phosphatases have high activ-
ities against PtdIns(4,5)P2 and PtdIns(3,4,5)P3 [7], and prefer-
ential hydrolysis of the lipids in vivo is also favored by their
being more abundant than Ins(1,4,5)P3 and Ins(1,3,4,5)P4 [8].
Thus, there is the ¢rm belief that any metabolic competition
between inositol lipids and inositol phosphates is of minimal
regulatory signi¢cance in vivo.
In this report, using structural, molecular and biochemical
approaches, we expand PTEN’s signaling repertoire by show-
ing it actively hydrolyzes inositol pentakisphosphate (InsP5)
to Ins(1,4,5,6)P4. This catalytic reaction generates an antago-
nist of PtdIns(3,4,5)P3 [9], and a putative transcriptional reg-
ulator [10], and may in£uence Rho-GTPase activation [11].
This metabolic competition between an inositol lipid and an
inositol phosphate adds a new, distinctive property to PTEN
functionality.
2. Materials and methods
2.1. Materials
[3H]Ins(1,3,4,5,6)P5 was prepared as previously described [12]. 14C-
labeled Ins(1,3,4,5)P4, Ins(1,3,4,6)P4 and D/L-Ins(1,4,5,6)P4 were iso-
lated from [14C]inositol-labeled, parotid acinar glands [13]. Non-ra-
dioactive Ins(1,3,4,5,6)P5 was supplied by CellSignals (Lexington,
KY, USA), and inositol hexakisphosphate (InsP6) was purchased
from Calbiochem (La Jolla, CA, USA). C4PtdIns(3,4,5)P3 was pur-
chased from Echelon (Salt Lake City, UT, USA). GST-PTEN was
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expressed in Escherichia coli, puri¢ed as previously described [3], and
kindly provided to us by Maehama and Dixon. The PTEN was stored
in aliquots at 370‡C. Earlier work also describes the DNA constructs
encoding FLAG-tagged PTEN under the control of the CMV pro-
moter in vector pCMV5 [3]. Recombinant human Ins(3,4,5,6)P4 1-
kinase was prepared as described previously [14]. The yeast protein
Arg-82, which shows Ins(1,4,5,6)P4 3-kinase activity, was prepared as
previously described [15].
2.2. PTEN transfection and inositol phosphate analysis of HEK293
cells
HEK293 cells (2U105 cells/well) were seeded in 6 well plates in
DMEM/10% fetal bovine serum and grown overnight at 37‡C in 5%
CO2. Cells were radiolabeled with 25 WCi/ml [3H]inositol (ARC, St.
Louis, MO, USA) for 3^4 days, and then each well was transfected
with 5 Wg plasmid DNA encoding PTEN or vector control using
Lipofectamine 2000 transfection reagent (Life Technologies, Gaithers-
burg, MD, USA) according to the manufacturer’s recommended pro-
tocol. After a further 4^6 h, lipid^DNA complexes were removed and
replaced with fresh complete medium, including [3H]inositol, for an
additional 36^48 h. Cells were quenched with 1 ml 2 M perchloric acid
supplemented with 0.1 mg/ml InsP6 and 2 mM EDTA. Lysates were
neutralized and analyzed by HPLC on a Partisphere SAX column as
previously described [15].
2.3. Western blotting and detection of FLAG-tagged proteins
Unlabeled HEK293 cells were grown and transfected as described
above. Cells were harvested by trypsinization, washed twice with
phosphate-bu¡ered saline (PBS), and frozen at 330‡C. Cell pellets
were subsequently thawed and lysed in 0.1 ml protein extraction bu¡-
er (50 mM L-glycerophosphate, pH 8.2, 250 mM sucrose, 150 mM
NaCl, 4 mM CHAPS, 50 mM NaF, 1 mM EDTA, 1 mM EGTA,
1 mM DTT, 250 WM AEBSF, 10 WM E-64, 1 Wg/ml leupeptin, 1 Wg/ml
pepstatin A). FLAG-tagged PTEN was detected using the anti-FLAG
M2 monoclonal antibody (Sigma, St. Louis, MO, USA), followed by
a horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody
(Amersham Pharmacia, Piscataway, NJ, USA). Protein concentration
was determined by Bradford analysis using bovine serum albumin
(BSA) as standard, and 25 Wg aliquots of cell extracts were subjected
to Western blotting from 10% polyacrylamide NuPAGE/Bis-Tris gels
(Invitrogen, Carlsbad, CA, USA) onto nitrocellulose membranes.
2.4. FLAG-PTEN puri¢cation
HEK293 cells were transfected with wild type (WT) or C124S mu-
tant FLAG-PTEN as described above. After 36^48 h, cells were tryp-
sinized, washed twice in PBS, and harvested in 0.5 ml protein extrac-
tion bu¡er (see above), but lacking NaF. Extracts were cleared by
centrifugation, and supernatants were incubated with 0.1 ml anti-
FLAG M2 agarose (Sigma) for 1^2 h at 4‡C with gentle rocking.
The beads were recovered by centrifugation, washed three times in
extraction bu¡er, and PTEN were released in 0.1 ml 0.5 M FLAG
peptide in Tris-bu¡ered saline (TBS) on ice for 30 min. A⁄nity puri-
¢ed proteins were separated by SDS^PAGE on 10% polyacrylamide
NuPAGE Bis-Tris gels and detected by silver staining. Protein con-
centration was determined by densitometry of stained gels using
known amounts of puri¢ed BSA (Pierce, Rockford, IL, USA) as a
standard.
2.5. Assays of inositol phosphate metabolism
PTEN was assayed in bu¡er comprising 50 mM HEPES (pH 7.2),
10 mM DTT, 0.1 mg/ml BSA. Samples were acid quenched, neutral-
ized and analyzed either by gravity-fed anion exchange columns [16]
or by HPLC [15].
3. Results and discussion
3.1. Hydrolysis of Ins(1,3,4,5)P4 by PTEN
PTEN is an active PtdIns(3,4,5)P3 3-phosphatase [3]. Our
determination of the Vmax for the substrate PtdIns(3,4,5)P3
(Table 1), is within the range (20^200 nmol/mg/min) typically
quoted for PTEN [17,18]. Analysis of the enzyme crystal
structure has previously predicted that the active site can ac-
commodate Ins(1,3,4,5)P4 [17], which represents the polar
head group of PtdIns(3,4,5)P3. However, a di¡erent study
indicated that the Km value for Ins(1,3,4,5)P4 is 99 WM, and
the Vmax value is only 8.5 nmol/mg/min [3]. The substrate
a⁄nity and Vmax value is much larger for PtdIns(3,4,5)P3
(Table 1). Thus, there has not previously been any serious
consideration that an inositol phosphate might be a physio-
logically relevant substrate for PTEN.
Surprisingly, we found that the a⁄nity of recombinant
PTEN for Ins(1,3,4,5)P4 (Km = 4.6 WM, Table 1) is s 20-
fold higher than the value previously determined by Maehama
and Dixon [3]. Moreover, our Vmax value for Ins(1,3,4,5)P4
(112 nmol/mg/min, Table 1) is 13-fold larger than previously
determined [3]. We have not studied why our kinetic param-
eters are so di¡erent from the earlier report, but it is impor-
tant to note that these preparations of PTEN were kindly
provided to us by Maehama and Dixon. Nevertheless, at lev-
els of 0.1^1 WM in vivo, Ins(1,3,4,5)P4 would not be expected
to appreciably compete with PtdIns(3,4,5)P3, which may reach
200 WM during cell activation [8]. However, our data
prompted us to study whether other inositol phosphates might
be more relevant substrates for PTEN.
Fig. 1. Molecular model of InsP5 accessing the active site of PTEN.
Using the modeling approach taken previously for Ins(1,3,4,5)P4
[17], we docked Ins(1,3,4,5,6)P5 (modeled using InsP6 from protein
data bank entry 1DKP) into the active site of PTEN (protein data
bank entry 1D5R). The additional 6-phosphate of InsP5 is easily ac-
commodated without steric con£icts. However, while the 2-hydroxyl
group can interact favorably with Asp-92, a 2-phosphate (as in
InsP6) clashes sterically with Asp-92 and would also be electrostati-
cally repelled.
Table 1
Kinetic parameters for PTEN
Substrate Km (WM) Vmax (nmol/mg/min)
C4PtdIns(3,4,5)P3 26 60
Ins(1,3,4)P3 11.5 24
Ins(1,3,4,5)P4 4.6 112
InsP5 7.1 67
Assay details are given in Section 2, and data represent mean values
from two to three experiments.
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3.2. Hydrolysis of Ins(1,3,4,5,6)P5 by PTEN
We used molecular modeling techniques to predict that the
active site of PTEN could accommodate InsP5 (Fig. 1). No
steric con£icts are predicted. In particular, the additional,
bulky 6-phosphate group (which is absent in Ins(1,3,4,5)P4
and PtdIns(3,4,5)P3) is predicted to be orientated away from
the surface of the protein (Fig. 1). This observation provides
an unexpected potential rationale for the large size of the
active site cleft in PTEN [17]. We next empirically veri¢ed
that recombinant PTEN dephosphorylated InsP5 (Table 1,
Fig. 2). The value of the Km was 7.1 WM, well below the
generally accepted physiological levels of this particular sub-
strate (15^50 WM [19,20]). In fact, PTEN has higher a⁄nity
for InsP5 than it does for PtdIns(3,4,5)P3, while the Vmax
values for both substrates are comparable (Table 1). Thus,
InsP5 is likely to be just as physiologically relevant a substrate
for PTEN as is PtdIns(3,4,5)P3, which provides the most no-
table exception to the general rule that there is little metabolic
competition between inositol phosphates and inositol lipids
(see Section 1).
Fig. 2. HPLC analysis of PTEN activity towards InsP5. A: PTEN (34 Wg) was incubated for 0 min (black circles) or 20 min (gray circles) at
37 ‡C in 200 Wl assay bu¡er (Table 1) containing 50 WM [3H]InsP5. Reactions were analyzed by HPLC using a Synchropak Q100 column. Ar-
rows mark the elution positions of 14C-labeled internal standards of Ins(1,3,4,6)P4, Ins(1,3,4,5)P4 and a Ins(1,4,5,6)P4/Ins(3,4,5,6)P4 mixture.
The PTEN-generated [3H]InsP4 product was further analyzed stereospeci¢cally; approx. 2000 dpm was incubated for 0 min (black circles) or
overnight (gray circles) with either (B) recombinant Ins(3,4,5,6)P4 1-kinase [14] or (C) recombinant Ins(1,4,5,6)P4 3-kinase (Arg-82); InsP5 accu-
mulation was measured by HPLC using a Partisphere SAX column.
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The signaling signi¢cance of PTEN-catalyzed InsP5 hydro-
lysis depends upon the reaction speci¢city. HPLC analysis
indicated InsP5 was dephosphorylated to a single InsP4 peak
that co-eluted with a standard Ins(1,4,5,6)P4/Ins(3,4,5,6)P4
mixture, which in turn was resolved from Ins(1,3,4,6)P4, Ins-
(1,3,4,5)P4, and the latter’s stereoisomer, Ins(1,3,5,6)P4 (Fig.
2A). This leaves Ins(3,4,5,6)P4 and Ins(1,4,5,6)P4 as the only
possible constituents of the InsP4 peak. However, further en-
zymatic analysis detected only Ins(1,4,5,6)P4 (Fig. 2B,C).
Thus, PTEN speci¢cally removes the 3-phosphate from InsP5,
forming Ins(1,4,5,6)P4. The high selectivity of PTEN for the
3-phosphate of PtdIns(3,4,5)P3 and InsP5 is reinforced by its
inability to hydrolyze either Ins(1,4)P2 or Ins(1,4,5)P3 (data
not shown, and [3]). Ins(1,3,4)P3 (Km = 11.5 WM, Table 1) was
a relatively weak substrate. InsP6 was not attacked by PTEN,
even when it was incubated at 20 times the level of enzyme
that completely dephosphorylated InsP5 (data not shown).
Indeed, our modeling analysis predicts that InsP6 is prevented
from accessing the active site by its 2-phosphate (Fig. 1,
legend). Thus, of all the inositol phosphates that we have
examined, Ins(1,3,4,5,6)P5 is the only one with any physiolog-
ical relevance as a substrate for PTEN.
The aforementioned experiments used bacterially expressed
PTEN. We next checked the catalytic activity towards InsP5
of FLAG-tagged PTEN which was expressed in human
HEK293 cells. The PTEN was a⁄nity puri¢ed using an im-
mobilized anti-FLAG antibody (Fig. 3, lane 1). 10 WM
[3H]InsP5 was hydrolyzed at a rate of 22 þ 7 nmol/mg/min
(n = 4), close to the approx. 35 nmol/mg/min of the bacterially
expressed enzyme (see Table 1). There was no detectable ac-
tivity in immunoprecipitates prepared from cells transfected
with vector alone. A C124S PTEN mutant (Fig. 3, lane 2),
known not to hydrolyze PtdIns(3,4,5)P3 or phosphoprotein
[3,17], was also inactive against InsP5 (6 1 nmol/mg/min).
The latter result con¢rms that InsP5 competes with both
PtdIns(3,4,5)P3 and phosphoproteins for the same active site
of PTEN. Occasions when this might have regulatory signi¢-
cance are during cell cycle progression [21], or upon cellular
di¡erentiation [22], whereupon regulated £uctuations in
Ins(1,3,4,5,6)P5 levels would seem likely to impact PTEN
activity towards its alternative substrates.
Moreover, the dephosphorylation of InsP5 to Ins(1,4,5,6)P4
itself has a number of important signaling consequences.
First, the PtdIns(3,4,5)P3 signaling pathway is antagonized
by Ins(1,4,5,6)P4, possibly because the latter competes for
certain PtdIns(3,4,5)P3 binding domains [9]. This suggests
PTEN undertakes bimodal deactivation of PtdIns(3,4,5)P3
signaling, since the accumulation of Ins(1,4,5,6)P4 is a nega-
tive signal that reinforces the consequences of dephosphory-
lation of PtdIns(3,4,5)P3 itself. Second, Ins(1,4,5,6)P4 has been
proposed to regulate transcription, at least in yeast [10]; in-
terestingly, some mammalian PTEN is nuclear [23]. Third, the
dephosphorylation of InsP5 to Ins(1,4,5,6)P4 is closely associ-
ated with Rho-GTPase activation [11].
3.3. PTEN is a unique Ins(1,3,4,5,6)P5 phosphatase
The only other known mammalian InsP5 3-phosphatase is
‘multiple inositol polyphosphate phosphatase’ (MIPP); how-
ever, the latter is closeted inside endoplasmic reticulum with
only restricted access to inositol phosphates [16]. The cytosolic
Ins(1,4,5,6)P4 3-kinase [20] was previously enigmatic in the
absence of a satisfactory explanation for an active pathway
of Ins(1,4,5,6)P4 synthesis. Now, however, we can appreciate
the occurrence of an ongoing Ins(1,3,4,5,6)P5 3-phosphatase/
Ins(1,4,5,6)P4 3-kinase substrate cycle in mammalian cytosol.
Perturbations in this cycle’s dynamic equilibrium are deleteri-
ous to cell function [16], and could be e¡ected upon relocation
of PTEN from the nucleus to the cytoplasm, as occurs during
neoplastic transformation of certain tumors [23].
There is a Mg2-independent, C(X)5R(S/T) phosphatase
consensus within the active site of PTEN. A virulence protein
in Salmonella, SopB, which cleaves the 3-phosphate from
Ins(1,3,4,5,6)P5 [9,11], also has C(X)5R(S/T) at the core of
its active site, but inositol lipids are hydrolyzed only weakly,
and with a di¡erent speci¢city (4-phosphatase) [24]. There are
also dedicated inositol lipid 4-phosphatases with the
C(X)5R(S/T) sequence [6]. Sac domains, which hydrolyze
PtdIns4P and some other inositol lipids, incorporate the
Fig. 3. Puri¢cation of recombinant PTEN from HEK293 cells.
HEK293 cells were transfected (Lipofectamine 2000) with 5 Wg plas-
mid DNA encoding either WT or C124S mutant FLAG-PTEN in
vector pCMV5. After 36^48 h, cells were lysed in 50 mM L-glycero-
phosphate, pH 8.2, 250 mM sucrose, 150 mM NaCl, 4 mM
CHAPS, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 250 WM
AEBSF, 10 WM E-64, 1 Wg/ml leupeptin, 1 Wg/ml pepstatin A.
PTEN was bound to anti-FLAG M2-agarose (Sigma), washed with
extraction bu¡er, and released with 0.5 M FLAG peptide in TBS.
Aliquots (10 Wl) of WT (lane 1) and C124S (lane 2) FLAG-PTEN
were separated by SDS^PAGE on 10% polyacrylamide NuPAGE
Bis-Tris gels and silver stained.
Fig. 4. E¡ect of PTEN upon [3H]InsP5 levels in HEK293 cells. A:
HEK293 cells were labeled with 25 WCi/ml [3H]inositol (ARC, St.
Louis, MO, USA) for 3^4 days, and then transfected (see Fig. 3,
legend) with either FLAG-PTEN (gray circles) or vector alone
(black circles). After 4^6 h, medium was replaced with fresh
[3H]inositol-supplemented medium for an additional 36^48 h. Cells
were quenched and analyzed by HPLC using a Synchropak Q100
column. Peaks were identi¢ed by comparison with the appropriate
standards. Data are representative of seven experiments (see text).
B: Anti-FLAG M2 monoclonal antibody (Sigma), followed by an
HRP-conjugated anti-mouse IgG antibody, was used for Western
blots of 25 Wg lysate, from vector-transfected (lane 1) or FLAG-
PTEN-transfected (lane 2) cells (see Fig. 3, legend).
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C(X)5R(S/T) motif [25]. We immunoprecipitated synaptojanin
from a rat brain extract [26] and assessed the catalytic activity
of its Sac domain as detailed in the Table 1 legend. The rate
of PtdIns4P hydrolysis was 4 pmol/min/Wl (no activity was
observed using preimmune sera). However, immunoprecipi-
tates of synaptojanin did not hydrolyze InsP5 (data not
shown). Thus, the catalytic site of PTEN is empowered with
unique coincident signaling properties.
3.4. Hydrolysis of Ins(1,3,4,5,6)P5 by PTEN in vivo
When PTEN was transfected into cells in earlier studies, it
had been assumed that any physiological e¡ects were due to
the protein’s PtdIns(3,4,5)P3 phosphatase and/or protein
phosphatase activities. In view of our discovery that PTEN
is an Ins(1,3,4,5,6)P5 3-phosphatase, we next determined if
enhanced InsP5 hydrolysis is observed upon ectopic PTEN
expression. We transiently transfected HEK293 cells with
FLAG-tagged PTEN, because some cell types cannot tolerate
long-term increases in cytosolic InsP5 phosphatase activity (at
least following overexpression of an aberrant MIPP lacking its
N-terminal endoplasmic reticulum-targeting sequence [16]). A
50 kDa FLAG-tagged protein was observed in PTEN-trans-
fected cells (Fig. 4B, lane 2, predicted size 47.4 kDa), but not
in vector-transfected controls (Fig. 4B, lane 1). HPLC (Fig.
4A) was used to assess InsP5 levels (which were normalized to
InsP6, which was una¡ected by PTEN transfection:
34473 þ 8879 dpm/sample in vector-transfected cells vs.
34173 þ 7464 dpm/sample in PTEN-transfected cells, n = 7).
In control cells, the ratio of InsP5/InsP6 was 0.71 þ 0.05
(n = 7). The corresponding ratio for PTEN-transfected cells
was 0.54 þ 0.05 (n = 7). This represents a signi¢cant decrease
of 25%. The degree of this e¡ect is remarkably close to the
30% decline in PtdIns(3,4,5)P3 levels previously observed fol-
lowing transient PTEN overexpression in HEK cells [2].
PTEN slightly increased levels of InsP4 (0.088 þ 0.01 in vec-
tor-transfected cells ; 0.12 þ 0.02 in PTEN-transfected cells)
but probably dephosphorylation of this InsP4 [9] prevented
it from accumulating further. Our data con¢rm that PTEN
does dephosphorylate InsP5 in vivo; this may contribute to
some of the phenotypic e¡ects that accompany PTEN over-
expression. A new dimension to future PTEN research will be
to study whether perturbations in the InsP5/Ins(1,4,5,6)P4
cycle also contribute to the neoplastic consequences of
PTEN gene mutations.
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